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ABSTRACT
We previously observed reduced YWHAE (14-3-3ε) protein expression in a small set 
of gastric cancer samples. YWHAE may act as a negative regulator of the cyclin CDC25B, 
which is a transcriptional target of MYC oncogene. The understanding of YWHAE role 
and its targets is important for the better knowledge of gastric carcinogenesis. Thus, 
we aimed to evaluate the relationship among YWHAE, CDC25B, and MYC in vitro and 
in vivo. For this, we analyzed the YWHAE, CDC25B, and MYC expression in YWHA-
silenced, CDC25B-silenced, and MYC-silenced gastric cancer cell lines, as well as in 
gastric cancer and non-neoplastic gastric samples. In gastric cancer cell lines, YWHAE 
was able to inhibit the cell proliferation, invasion and migration through the reduction 
of MYC and CDC25B expression. Conversely, MYC induced the cell proliferation, invasion 
and migration through the induction of CDC25B and the reduction of YWHAE. Most of the 
tumors presented reduced YWHAE and increased CDC25B expression, which seems to 
be important for tumor development. Increased MYC expression was a common finding 
in gastric cancer and has a role in poor prognosis. In the tumor initiation, the opposite 
role of YWHAE and CDC25B in gastric carcinogenesis seems to be independent of MYC 
expression. However, the inversely correlation between YWHAE and MYC expression 
seems to be important for gastric cancer cells invasion and migration. The interaction 
between YWHAE and MYC and the activation of the pathways related to this interaction 
play a role in the metastasis process.
INTRODUCTION
Gastric cancer (GC) is one of the most common 
causes of cancer death in the World [1]. Advanced GC 
presents few treatment options and a poor prognosis, 
which is in part due to the tumor recurrence, invasion 
or metastasis. The relative five-year survival rate is 
below than 20% [2]. It is still necessary to determine 
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the key molecular factors involved in GC initiation and 
progression.
In eukaryotes, the 14-3-3s are part of a highly 
conserved protein family. Seven 14-3-3 genes encode 
nine protein isoforms, including two phosphorylated forms 
(α and δ) [3, 4]. The 14-3-3 proteins are mainly dimeric 
within the cell and are able to bind several sites within a 
target or act as a bridge between proteins [5–7]. 14-3-3 
proteins can interact with hundreds of proteins, including 
cdc25 phosphatase [4, 5, 7, 8]. The precise function of 
14-3-3 proteins is not fully understand. However, these 
proteins seem to play a role as molecular scaffolds [4] and 
regulate different biologic processes, including apoptosis, 
mitogenic signal transduction, and cell cycle (for reviews, 
see references [5, 9, 10]).
Deregulated expression of 14-3-3 proteins has 
been detected in some GC proteomic studies [11–14]. We 
previously observed reduced YWHAE, also called 14-3-
3ε, protein expression in a small set of GC specimens [15]. 
Reduced YWHAE expression has also been described in 
other cancers [16–18], suggesting that this protein may 
play a role as a tumor suppressor.
YWHAE acts as a negative regulator of CDC25 [19, 
20]. CDC25 phosphatases play a key role in cell cycle 
proliferation. CDC25B seems to present oncogenetic 
properties [21] and its overexpression was described 
previously in GC [22–25]. The subcellular localization of 
CDC25B can be controlled by its association with 14-3-3 
proteins. CDC25B subcellular location might contribute to 
stall the cell cycle at the G2 phase following DNA damage 
[26–29].
At the transcription level, CDC25B is also a target 
of MYC and they may mediate MYC-induced cell cycle 
activation and/or apoptosis [30]. A correlation between 
CDC25B and MYC immunoreactivity was earlier 
described in GC [25]. MYC, located at 8q24, is a key 
oncogene in gastric carcinogenesis [31]. We previously 
demonstrated that MYC mRNA and protein increased 
expression is a common finding in GC samples [32–35] 
and some preneoplastic gastric lesions [36, 37] from a 
Brazilian population. Our research group also showed 
MYC expression increases during gastric carcinogenesis 
in a nonhuman primate model [38]. Moreover, we 
described several genetic and epigenetic alterations 
involving MYC gene in GC samples or GC cell lines, 
including chromosome 8 trisomy [32, 39–43], gene or 
8q24 amplification [32–36, 39, 44–46], gene insertion 
[47], promoter hypomethylation [34] and point mutations 
[34]. However, the understanding of MYC targets is 
important for the better knowledge of its role in gastric 
carcinogenesis and may help in the development of new 
anticancer therapies.
Based on our previous findings, we hypothesized 
that MYC or CDC25B up-regulation may induce YWHAE 
down-regulation in GC or YWHAE down-regulation 
would induce CDC25B up-regulation in this neoplasia, 
which would also contribute to MYC overexpression. In 
this study, we aimed to better understand the relationship 
of the expression of these genes in vivo and in vitro. For 
this, we simultaneously evaluated the YWHAE, CDC25B, 
MYC and mRNA and protein expression in GC cell 
lines and in a large set of GC and paired non-neoplastic 
gastric samples. Additionally, we investigated the possible 
associations between gene/protein expression and clinical 
variables.
RESULTS
mRNA and protein expression in gastric cell 
lines
We firstly accessed the mRNA and protein 
expression of YWHAE, CDC25B and MYC in GC cell lines 
in relation to the non-neoplastic MNP01 cells (Figure 1). 
GC cell lines presented a reduced YWHAE mRNA and 
protein expression in relation to MNP01 cells [mRNA 
median (interquartile range, IQR): 0.71 (0.31); protein 
median (IQR): 0.52 (0.40); respectively]. On the other 
hand, the GC cell lines presented an increased CDC25B 
[mRNA median (IQR): 1.79 (1.15); protein median (IQR): 
Figure 1: YHWAE, CDC25B and MYC mRNA and protein expression in gastric cancer cell lines in relation to non-
neoplastic cells. MNP01 non-neoplastic cells were used as a calibrator. Values of median and IQR are shown.
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1.45 (1.24); respectively] and MYC [mRNA median 
(IQR): 2.98 (1.13); protein median (IQR): 2.48 (0.66); 
respectively] expression.
YWHAE silencing induces GC cell proliferation, 
invasion and migration
siRNA decresead YWHAE expression in more 
thand 80% in ACP03 and in more than 90% in AGP01 
and ACP02 cell lines (Figure 2A–2B). Furthermore, 
YWHAE silencing induced cell proliferation (p<0.05, 
for all comparisions; Figure 3A–3C) and induces cell 
arrest by increase of G1/G0 cells and decrease in cells 
in S and G2/M (p<0.05, for all comparisions; Figure 
4A–4C).
YWHAE silencing induced cell invasion and 
migration in all gastric cancer cell lines (p<0.05, for all 
comparisions; Figure 5A).
Figure 2: Effect of gene silencing in gene and protein expression in gastric cancer cell lines. A. YWHAE silencing induced 
MYC and CDC25B increased expression in GC cell lines. B. GC cells with (+) or without (-) YWHAE silencing, equal amounts of whole cell 
extracts were analyzed by western blot with the indicated antibodies. C. CDCD25B silencing did not alter MYC and YHWAE expression in 
GC cell lines. D. GC cells with (+) or without (-) CDC25B silencing; Equal amounts of whole cell extracts were analyzed by western blot 
with the indicated antibodies. E. MYC silencing induced the reduction of CDC25B expression and increasing of YHWAE expression in GC 
cell lines. F. GC cells with (+) or without (-) MYC silencing; equal amounts of whole cell extracts were analyzed by western blot with the 
indicated antibodies. siRNA control-transfected cells were used as a calibrator. Values of median and IQR are shown.
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YWHAE regulates CDC25B and MYC in GC 
cells
YWHAE silencing induced CDC25B up-regulation 
by at least 1.6-fold in all GC cell lines (Figure 2A) and a 
slight MYC up-regulation by approximately 1.25-fold in 
all GC cell lines (Figure 2A). At protein level, YWHAE 
expression was inversely correlated with MYC (ρ=-
0.697; p=0.037; Figure 6A) and CDC25B expression (ρ=-
0.676; p=0.046; Figure 6B). MYC and CDC25B protein 
expression was also correlated in YWHAE silencing cells 
(ρ=0.854; p=0.003; Figure 6C).
Then, we silenced CDC25B and MYC in GC 
cell to evaluate the effect of these genes in GC cells, 
as well as the effect on YWHAE expression. siRNA 
caused a reduction in CDC25B expression of more 
than 80% in all three GC cell lines (Figure 2C–2D). 
Although CDC25B silencing induced a significant 
decrease in cell proliferation (Figure 3D–3F), control 
cells were accumulated in G1 in relation to si-CDC25B 
cells (p<0.05, for all comparisions; Figure 4D–4F). 
CDC25B silencing inhibits GC cells invasion and 
migration (Figure 5B). However, CDC25B silencing did 
not induced alteration in MYC or YWHAE mRNA and 
protein expression (Figure 2B).
Conversely, siRNA caused a reduction in MYC 
expression of more than 70% in all three studied GC 
cell lines (Figure 2E–2F). The cell lines also presented 
significant alterations concerning cell proliferation. All 
cell lines presented a significant decrease in proliferation 
after 48 h and 72 h of silencing MYC (p<0.05, for all 
comparisons; Figure 3G–3I). Moreover, ACP02 and 
ACP03 also showed a reduction in cell proliferation after 
24 h of MYC silencing (p<0.05, for all comparisons; 
Figure 3G–3I). After 72 h, MYC silencing leads to 
alterations in the GC cell cycle. Slight variations were 
observed among GC cell lines (Figure 4G–4I). Control 
cells were accumulated in G1, and there was a statistical 
significance when comparing control cells to siRNA-
MYC cells (p<0.05, for all comparisions), as detected in 
si-CDC25B cells. Furthermore, MYC silencing inhibed GC 
cells invasion and migration (p<0.05, for all comparisions; 
Figure 5C).
Figure 3: Effect of gene silencing in gastric cancer cell proliferation. A. Effect of YWHAE silencing in AGP01 cell line. B. Effect 
of YWHAE silencing in ACP02 cell line. C. Effect of YWHAE silencing in ACP03 cell line. D. Effect of CDC25B silencing in AGP01 cell 
line. E. Effect of CDC25B silencing in ACP02 cell line. F. Effect of CDC25B silencing in ACP03 cell line. G. Effect of MYC silencing in 
AGP01 cell line. H. Effect of MYC silencing in ACP02 cell line. I. Effect of MYC silencing in ACP03 cell line. Cell counting was measured 
after 24, 48, and 72 h of silencing. *p<0.05, significant difference between controls and silenced cells by Mann-Whitney test. Values of 
median and IQR are shown. siCT: controls cells; siYWHAE: cells with YWHAE silencing; siCDC25B: cells with CDC25B silencing; 
siMYC: cells with MYC silencing.
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We next evaluate whether MYC may regulate 
YWHAE and CDC25B in gastric cells. MYC silencing 
induced CDC25B down-regulation by at least 4-fold in 
all GC cell lines (Figure 2E). Conversely, MYC silencing 
up-regulated YWHAE by approximately 1.5-fold in all 
GC cell lines (Figure 2E). Considering all cell lines, we 
observed that MYC expression was directly correlated 
with CDC25B expression (ρ=0.996; p<0.001; Figure 7A) 
and inversely correlated with YWHAE expression (ρ=-
0.996; p<0.001; Figure 7B). Moreover, a strong inverse 
correlation was detected between YWHAE and CDC25B 
expression (ρ=-0.992; p<0.001; Figure 7C). MYC and 
YWHAE protein expression was also inversely correlated 
(ρ=-0.703; p<0.033).
YWHAE, CDC25B, and MYC expression in 
gastric samples
YWHAE immunoreactivity was detected in the 
cytoplasm of lymphocytes and non-neoplastic gastric cells 
(Figure 8A). YWHAE immunoreactivity was observed in 
only 6 (4.7%) of the gastric tumor tissue samples (Figure 
8B). CDC25B was detected in the nuclei and cytoplasm 
of 128 (99.2%) GC samples (Figure 8D). Nuclear 
immunoreactivity for MYC was detected in 117 (90.7%) 
GC samples (Figure 8F). Conversely, nonatypical gastric 
cells did not present CDC25B and MYC immunoreactivity 
(Figure 8C and 8E).
Down-regulation (at least 50% decrease in 
expression) of YWHAE protein and mRNA was detected 
in 89 (69%) and 61 (47.3%) GC samples, respectively 
(Figure 9A–9B, G).
Conversely, protein and mRNA levels of CDC25B 
were increased more than 1.5-fold (increment of at least 
50% in expression) in 72 (55.8%) and 77 (59.7%) GC 
samples, respectively (Figure 9C–9D, G). In addition, 
MYC protein and mRNA expression increased more than 
1.5-fold in 101 (78.3%) and 129 (100%) GC samples, 
respectively, in comparison to paired non-neoplastic 
gastric specimens (Figure 9E–9F, G).
MYC (p=0.002 and 0.001, respectively) 
and YWHAE (p=0.007 and <0.001, respectively) 
immunoreactivity was associated with higher protein 
and mRNA levels in GC samples. A strong correlation 
was observed between mRNA and protein expression 
for YWHAE (ρ=0.759; p<0.001; Figure 10A), CDC25B 
Figure 4: Effect of si-RNA silencing on cell cycle progression of gastric cancer cell lines. A. Effect of YWHAE silencing in 
AGP01 cell line. B. Effect of YWHAE silencing in ACP02 cell line. C. Effect of YWHAE silencing in ACP03 cell line. D. Effect of CDC25B 
silencing in AGP01 cell line. E. Effect of CDC25B silencing in ACP02 cell line. F. Effect of CDC25B silencing in ACP03 cell line. G. 
Effect of MYC silencing in AGP01 cell line. H. Effect of MYC silencing in ACP02 cell line. I. Effect of MYC silencing in ACP03 cell line. 
The cell cycle analysis was performed at 72 h after transfection. *p<0.05, significant difference between controls and silenced cells by 
Mann-Whitney test. Values of median and IQR are shown. siCT: controls cells; siYWHAE: cells with YWHAE silencing; siCDC25B: cells 
with CDC25B silencing; siMYC: cells with MYC silencing.
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Figure 5: Effect of si-RNA silencing on gastric cancer cell lines invasion and migration. A. Effect of YWHAE silencing in 
GC cell line. B. Effect of CDC25B silencing in GC cell line. C. Effect of MYC silencing in GC cell line. *p<0.05, significant difference 
between controls and silenced cells by Mann-Whitney test. Values of median and IQR are shown. siCT: controls cells; siYWHAE: cells 
with YWHAE silencing; siCDC25B: cells with CDC25B silencing; siMYC: cells with MYC silencing.
Figure 6: Correlation between protein expression in YWHAE-silenced AGP01, ACP02 and ACP03 gastric cancer cell 
lines. A. YWHAE and MYC. B. YWHAE and CDC25B. C. MYC and CDC25B. Correlation coefficients and p-values of Spearman 
correlation test are shown. *p<0.05, significant correlation by Spearman correlation test.
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(ρ=0.972; p<0.001; Figure 10B), and MYC (ρ=0.968; 
p<0.001; Figure 10C).
An inverse correlation was detected between 
YWHAE and CDC25B protein (ρ=-0.692; p<0.001; 
Figure 11A) and mRNA (ρ=-0.857; p<0.001; Figure 11B) 
expression. Moreover, 122 (94.6%) of tumors presented 
CDC25B immunoreactivity and lack of YWHAE 
immunostaining.
MYC protein and mRNA expression was not 
correlated with CDC25B or YWHAE expression (p>0.05 
for all analyses). However, 117 (90.7%) of the tumors 
presented both MYC and CDC25B immunoreactivity, and 
111 (86%) of the tumors presented MYC immunoreactivity 
and lack of YWHAE immunostaining.
We used the K-means clustering method to group 
samples based on their gene expression similarities. 
In the K-means clustering method, we observed the 
presence of two clusters. In both clusters, a strong 
inverse correlation was also detected between YWHAE 
and CDC25B mRNA (ρ=-0.844, p<0.001, Figure 12A 
for “Cluster 1” and ρ=-0.868, p<0.001, Figure 12G for 
“Cluster 2”) and protein (ρ=-0.737, p<0.001, Figure 12D 
for “Cluster 1” and ρ=-0.657, p<0.001, Figure 12J for 
“Cluster 2”) expression. In one of the clusters (named 
Figure 8: YWHAE, CDC25B and MYC immunoreactivity in gastric tissue samples. A. Non-neoplastic gastric mucosa 
showing cytoplasmic YWHAE staining. B. intestinal-type gastric cancer cells without YWHAE immunoreactivity. C. Non-neoplastic gastric 
tissue without CDC25B immunoreactivity. D. Diffuse-type gastric cancer presenting nuclear and cytoplasmic CDC25B immunoreactivity. 
E. Gastric mucosa without MYC immunoreactivity. F. Intestinal-type gastric cancer presenting nuclear immunoreactivity of MYC.
Figure 7: Correlation between the studied genes mRNA expression in MYC-silenced AGP01, ACP02 and ACP03 
gastric cancer cell lines. A. MYC and CDC25B. B. MYC and YWHAE. C. CDC25B and YWHAE. Correlation coefficients and p-values 
of Spearman correlation test are shown. *p<0.05, significant correlation by Spearman correlation test.
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Figure 9: Protein and gene expression in gastric cancer. A. YWHAE protein expression. B. YHWAE mRNA expression. C. 
CDC25B protein expression. D. CDC25B mRNA expression. E. MYC protein expression. F. MYC mRNA expression. G. Representative 
image of Western-blot. In all graphs, the expression in gastric tumors was normalized by matched non-neoplastic gastric tissue. T: tumor 
sample; N: normal mucosa sample; RQ: relative quantification. The whiskers indicate the minimum and maximum values. The dotted lines 
representes the 1.5 fold-change.
Figure 10: Correlation between protein and mRNA expression in gastric cancer samples. A. YWHAE. B. CDC25B. 
C. MYC. Correlation coefficients and p-values of Spearman correlation test are shown. *p<0.05, significant correlation by Spearman 
correlation test.
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“Cluster 2”), MYC mRNA and protein expression was 
directly correlated with CDC25B expression (ρ=0.409, 
p=0.001, Figure 12I; ρ=0.400, p=0.001, Figure 12L; 
respectively) and inversely correlated with YWHAE 
mRNA expression (ρ=-0.340, p=0.007, Figure 12H). 
Interestingly, “Cluster 2” was composed of samples with 
the highest MYC expression, in which the mRNA level 
was increased by at least 3.2-fold and protein level was 
increased by at least 1.8-fold.
Association between YWHAE, CDC25B, and 
MYC expression with clinicopathological 
features in GC
Clinicopathological variables and YWHAE, 
CDC25B, and MYC expression are shown in Table 1. 
YWHAE protein expression was reduced in tumors of 
male in relation to tumors of females (p=0.046; Table 1).
The cancer samples of patients with late-onset 
tumors presented higher YWHAE and MYC expression 
and lower CDC25B expression in relation to to early-onset 
GC samples (p<0.05 for all analyses; Table 1).
YWHAE protein and mRNA expression was 
reduced in diffuse-type GC (p<0.001 and 0.019, 
respectively; Table 1). Conversely, CDC25B protein 
and mRNA expression was increased in diffuse-type 
GC (p=0.041 and 0.027, respectively; Table 1). MYC 
immunoreactivity was more frequent in intestinal-type GC 
(p=0.010; Table 1).
Decreased YWHAE protein and mRNA expression 
was also associated with early-stage and T1/T2 tumors 
(p<0.05 for all comparisons; Table 1). In contrast, 
Figure 11: Correlation between YWHAE and CDC25B in all the studied gastric cancer samples. A. protein expression. 
B. mRNA expression. Correlation coefficients and p-values of Spearman correlation test are shown. *p<0.05, significant correlation by 
Spearman correlation test.
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CDC25B protein and mRNA expression was higher in 
T1/T2 tumors in relation to T3/T4 tumors (p<0.05 for 
all analyses; Table 1). CDC25B protein expression was 
also increased in early-stage tumors in comparison to 
advanced-stage tumors (p=0.046; Table 1).
Increased MYC expression was detected in tumors 
with advanced stage, deeper invasion, lymph node and 
distant metastases and with EBV infection (p<0.05 for all 
analyses; Table 1). Moreover, MYC immunoreactivity was 
more frequent in tumors of patients with lymph node or 
distant metastases (p<0.05 for all analyses; Table 1).
YWHAE expression seems to increase and 
CDC25B expression seems to reduce between stages I 
and III; however, we did not detect a significant change 
among tumor stages after Bonferroni adjustment (p>0.008; 
Figure 13A–13D). A gradual increase of MYC expression 
was detected in GC samples through tumor stages I to IV 
(p<0.008 for all analyses; Mann-Whitney test followed by 
Bonferroni correction; Figure 13E–13F).
The inverse correlation between YWHAE and 
CDC25 mRNA and protein expression was independent 
of the tumor stage, tumor invasion or ocurrence of lymph 
Figure 12: Correlation between mRNA and protein expression in two cluster of gastric cancer samples. A. YWHAE 
and CDC25B mRNA expression in the cluster 1. B. YWHAE and MYC mRNA expression in the cluster 1. C. CDC25B and MYC mRNA 
expression in the cluster 1. D. YWHAE and CDC25B protein expression in the cluster 1. E. YWHAE and MYC protein expression in 
the cluster 1. F. CDC25B and MYC protein expression in the cluster 1. G. YWHAE and CDC25B mRNA expression in the cluster 2. H. 
YWHAE and MYC mRNA expression in the cluster 2. I. CDC25B and MYC mRNA expression in the cluster 2. J. YWHAE and CDC25B 
protein expression in the cluster 2. K. YWHAE and MYC protein expression in the cluster 2. L. CDC25B and MYC protein expression in 
the cluster 2. Correlation coefficients and p-values of Spearman correlation test are shown. *p<0.05, significant correlation by S Spearman 
correlation test.
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Table 1: Clinicopathological variables and gene expression in GC
Variable N
YWHAE 
immunoreactivity
YWHAE  
protein
YWHAE mRNA CDC25B 
immunoreactivity
CDC25B 
protein
CDC25B 
mRNA
MYC 
immunoreactivity
MYC protein MYC mRNA
N (%)  
of 
positive 
cases
p  
valuea
Ratio  
T/N 
[median 
(IQR)]
p  
valueb
RQ 
[median 
(IQR)]
p  
valueb
N (%)  
of  
positive 
cases
p  
valuea
Ratio  
T/N  
[median 
(IQR)]
p 
valueb
RQ 
[median 
(IQR)]
p 
valueb
N (%)  
of  
positive  
cases
p  
valuea
Ratio  
T/N  
[median 
(IQR)]
p 
valueb
RQ 
[median 
(IQR)]
p 
valueb
Gender
 Female 45 2 (4.4) 0.652 0.57  (0.26) 0.046*
0.64 
(0.32)
0.592 45 (100) 0.651 1.71 
(0.73)
0.349
1.68 
(0.61) 0.376 41 (91.1) 0.589
2.11 
(1.55) 0.687
3.22 
(1.38)
0.953
 Male 84 4 (4.8) 0.49 
(0.33)
0.69 
(0.30)
83 
(98.8)
1.61 
(0.66)
1.61 
(0.60) 76 (90.5)
2.16 
(1.18)
3.11 
(1.09)
Onset
 < 45 years 34 3 (8.8) 0.187
0.41 
(0.27) 0.006*
0.49 
(0.21) <0.001*34 (100) 0.736
1.96 
(0.50) 0.003*
1.88 
(0.40)
0.005* 2 (94.1) 0.339
1.80 
(0.92) 0.013*
3.04 
(1.27) 0.048*
 ≥ 45 years 95 3 (3.2) 0.57 (0.29)
0.71 
(0.23)
94 
(99.2)
1.45 
(0.61)
1.57 
(0.52) 85 (89.5)
2.23 
(1.27)
3.28 
(1.01)
Tumor location
 Cardia 50 1 (2) 0.247 0.57 (0.25) 0.379
0.68 
(0.22) 0.489 50 (100) 0.612
1.64 
(0.64)
0.625 1.61 
(0.53)
0.383 43 (86) 0.126 1.87 (1.27) 0.088
3.06 
(1.32)
0.197
 Non-cardia 79 5 (6.3) 0.49 
(0.34)
0.66 
(0.35)
78 
(98.7)
1.62 
(0.72)
1.68 
(0.64)
74 (93.7)
2.20 
(1.16)
3.23 
(0.93)
Histological type
 Diffuse 62 3 (4.8) 0.622 0.39 (0.25) <0.001*
0.58 
(0.33)
0.019* 62 (100) 0.519 1.84 (0.72) 0.041*
1.78 
(0.62) 0.027* 52 (83.9) 0.010*
2.20 
(1.13)
0.786
3.21 
(0.92) 0.854
 Intestinal 67 3 (4.5) 0.63 (0.22)
0.72 
(0.26)
66 
(98.5)
1.43 
(0.57)
1.52 
(0.50) 65 (97)
2.11 
(1.40)
3.09 
(1.22)
Stage
 Early 12 0 (0) 0.550 0.36 
(0.28)
0.027*
0.48 
(0.19) 0.003* 12 (100) 0.907
1.83 
(0.45)
0.102 1.80 
(0.33)
0.046* 10 (83.3) 0.309
1.37 
(0.60) <0.001*
2.25 
(1.25) 0.003*
 Advanced 117 6 (5.1) 0.55 (0.29)
0.68 
(0.29)
116 
(99.1)
1.61 
(0.68)
1.62 
(0.60)
107 
(91.5)
2.19 
(1.24)
3.23 
(1.03)
Tumor invasion
 T1/T2 42 0 (0) 0.089 0.42 
(0.28)
0.006*
0.57 
(0.23)
0.001* 42 (100) 0.674
1.79 
(0.42)
0.004*
1.76 
(0.33)
0.004* 36 (85.7) 0.151 1.63 (0.77) <0.001*
2.59 
(1.12) <0.001*
 T3/T4 87 6 (6.9) 0.58 
(0.28)
0.72 
(0.29)
86 
(98.9)
1.35 
(0.67)
1.48 
(0.62) 81 (93.1)
2.38 
(1.20)
3.40 
(0.95)
Lymph node metastasis
 Absent 16 1 (6.3) 0.556 0.52 (0.27) 0.379
0.62 
(0.27) 0.438
15 
(93.8)
0.124
1.93 
(0.65) 0.092
1.86 
(0.58)
0.123 11 (68.8) 0.007*
1.42 
(0.25) <0.001*
2.36 
(0.48)
<0.001*
 Present 113 5 (4.4)
0.55 
(0.31)
0.67 
(0.32)
113 
(100)
1.61 
(0.65)
1.62 
(0.59)
106 
(93.8)
2.23 
(1.21)
3.29 
(0.97)
Distant metastasis
 Absent 70 3 (4.3) 0.576 0.57 
(0.30)
0.134
0.67 
(0.27) 0.970
69 
(98.6)
0.543
1.63 
(0.69) 0.620
1.63 
(0.59) 0.712 58 (82.9) <0.001*
1.67 
(0.61) <0.001*
2.63 
(0.76) <0.001*
 Present 59 3 (5.1) 0.49 
(0.32)
0.66 
(0.36)
59 (100) 1.63 
(0.68)
1.67 
(0.64)
59 (100) 2.93 (0.96)
3.74 
(0.44)
H. pylori
 Negative 13 0 (0) 0.522 0.39 
(0.31)
0.109 0.57 
(0.35)
0.315 13 (100) 0.899
1.76 
(0.82)
0.134
1.72 
(0.68)
0.127 12 (92.3) 0.654 2.17 
(1.41)
0.879
3.02 
(1.27) 0.656
 Positive 116 6 (5.2) 0.55 
(0.31)
0.67 
(0.30)
115 
(99.1)
1.62 
(0.68)
1.63 
(0.60) 105(90.5)
2.14 
(1.30)
3.21 
(1.16)
CagA
 Negative 46 0 (0) 0.066 0.54 
(0.32)
0.611 0.66 
(0.30)
0.508
45 
(97.8)
0.357
1.63 
(0.71) 0.526
1.63 
(0.55) 0.665 41 (89.1) 0.435
2.08 
(1.15) 0.789
3.17 
(1.05) 0.904
 Positive 83 6 (7.2) 0.56 
(0.31)
0.70 
(0.33)
83 (100)
1.64 
(0.69)
1.65 
(0.66) 76 (91.6)
2.18 
(1.33)
3.17 
(1.14)
EBV
 Negative 108 4 (3.7) 0.252 0.54 
(0.30)
0.742
0.67 
(0.30)
0.723
107 
(99.1) 0.837
1.64 
(0.69) 0.730
1.64 
(0.57) 0.990 96 (88.9) 0.107
2.04 
(1.14)
0.024*
3.08 
(1.10) 0.025*
 Positive 21 2 (9.5) 0.58 
(0.36)
0.64 
(0.34)
21 (100) 1.39 
(0.68)
1.60 
(0.66) 21 (100)
2.57 
(1.71)
3.69 
(1.19)
ap value by χ2 test; bp value by Mann-Whitney test. *p<0.05, significantly difference between groups. **A tendency for 
different expression between groups. N: number of samples; T/N: ratio of protein expression between neoplastic and 
matched non-neoplastic samples; RQ: relative quantification, in which the matched non-neoplastic sample was designated 
as a calibrator from each neoplastic samples; IQR: interquartile range; EBV: Epstein-Barr virus.
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node and distant metastases (p<0.05; for all comparisons). 
Interestingly, YWHAE and MYC expression was directly 
correlated (ρ=0.361; p=0.002) and CDC25B and MYC 
expression was inversely correlated (ρ=-0.271; p=0.023) 
in tumors of patients without distant metastasis. However, 
in tumors of patients with distant metastasis or in stage IV 
GC, MYC and CDC25B mRNA expression was positively 
correlated (ρ=0.269; p<0.039) and MYC and CDC25B 
protein expression also tended to be correlated (ρ=0.248; 
p=0.058).
Moreover, the “Cluster 2” described above was 
associated with advanced GC stage, deeper tumor invasion 
(T stage), the occurrence of lymph node metastasis and the 
occurrence of distant metastases (p<0.05 for all analyses; 
Supplementary Table S1).
DISCUSSION
Reduced YWHAE expression was described in 
different types of cancer, including lung [16], larynx [17], 
and brain [18] cancers. Our group also detected reduced 
expression of YWHAE in a smaller GC samples cohort 
[15]. Although these findings provide evidences to support 
classification of YWHAE as a tumor suppressor gene, the 
precise role of this gene in gastric carcinogenes was still 
unknown.
In vitro, we demonstrated that YWHAE acts as a 
tumor suppressor in GC inducing cell arrest and inhibiting 
cell invasion and migration through the down-regulation 
of MYC and CDC25B. On the other hand, MYC oncogene 
is able to induces GC cell proliferation, invasion and 
migration through the up-regulation of CDC25B and 
down-regulation of YWHAE. Our findings suggest that 
YWHAE and MYC may have a opposite role in GC 
cells. A previous study showed that the knockdown of 
another member of 14-3-3 family, the YWHAS, leads to 
increased expression of MYC protein [48]. Thus, other 
14-3-3 family member can regulates MYC during gastric 
carcinogenesis.
In tissue samples, YWHAE immunoreactivity was 
detected in only approximately 5% of tumors and its 1.5-
fold reduced protein and mRNA expression was observed 
in aproximately 70% and 50% of the studied tumors, 
respectively. Moreover, none of the tumors presented 
the YWHAE expression higher than the matched non-
neoplastic gastric sample. This findings confirm that 
Figure 13: Protein and mRNA expression by tumor stage. A. YWHAE protein expression. B. YWHAE mRNA expression. 
C. CDC25B protein expression. D. CDC25B mRNA expression. E. MYC protein expression. F. MYC mRNA expression. *p<0.008, 
significant difference between groups (Mann-Whitney test followed by Bonferroni corrections); **p<0.001, significant difference between 
groups (Mann-Whitney test followed by Bonferroni corrections); #p<0.05, difference between groups but not statistically significant after 
Bonferroni adjustment. Values of median and IQR are shown.
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YWHAE may act as a tumor suppressor as observed 
in vitro and as described previously by our group in 
a smaller GC samples cohort [15]. On the contrary, 
CDCD25B immunoreactivity was observed in almost 
all tumors and its mRNA and protein expression was 
increased by at least 1.5-fold in more than 50% of the 
cases in relation to non-neoplastic samples. However, it 
is important to highlight that only two samples presented 
the ratio of CDC25B protein expression between tumor 
and corresponding non-neoplastic specimens below 1 
in the studied cohort. This finding is in agreement with 
the oncogenic role of CDC25B in GC samples from our 
admixed population (mainly composed by European, 
Africans, and Amerindians [49]) as already described in 
GC samples from patients from East Asian [22–25].
Although direct silencing of CDC25B did not altered 
YWHAE expression, CDC25B and YWHAE expression 
were inversely correlated in MYC or YWHAE silenced 
cells, as well as in GC samples. YWHAE negatively 
regulates CDC25 [19, 20]. The hypothesis of CDC25B 
negative regulation by YWHAE in gastric carcinogenesis 
is also supported by our findings concerning the 
association of these genes or proteins expression and 
clinicopathological features. Reduced YWHAE and 
increased CDC25B expression was associated with early-
onset GC, diffuse-type, T1/T2 stage, and early-stage 
tumors.
Our group previously described the association or 
tendency to association of reduced YWHAE expression 
with early-onset GC, diffuse-type, T1/T2 stage, and 
early-stage GC [15]. Thus, our findings reinforce that 
decreasing of YWHAE expression may be important for 
tumor initiation, especially in diffuse-type tumors an of 
early-onset. Early-onset GC presents distinct molecular 
and clinicopathological pattern in relation to late-onset 
tumors, which suggest that they are a two subsets of 
GC [50–52]. Furthermore, our results also supports that 
the intestinal and diffuse histological GC types follow 
different molecular pathways and may be two separate 
entities [53].
Although our results suggest that the highest level of 
CDC25B expression seems be important for GC initiation 
in our population, previous studies described its increased 
expression associated with advanced tumor stage, deeper 
invasion, and metastasis in East Asian population [22–24]. 
As described above, the expression of CDC25B was up-
regulated in most of the studied GC samples, despite the 
invasion or metastasis. Further studies are still required to 
improve the knowledge about CDC25B function during 
GC progression; however, it is important to highlight that 
this is the largest cohort of GC and paired non-neoplastic 
gastric specimens in which CDC25B expression was 
evaluated.
Interestingly, even although not statistically 
significant, YWHAE expression was increased and 
CDC25B expression was reduced continuously between 
stages I to and III. However, in the stage IV, YWHAE 
expression returns to decrease and CDC25B expression 
returns to increase. In this stage, the highest MYC 
expression was detected. Here, we observed that only 
in GC samples with highest MYC expression, MYC 
expression was directly correlated with CDC25B 
expression and inversely correlated with YWHAE 
expression, such as observed in GC cell lines.
In GC samples from a Chinese population, a 
correlation between MYC and CDC25B immunoreactivity 
was described [25]; however, the effect of tumor stage in 
the immunoreactivity of these proteins was not accessed. 
MYC is able to regulate the transcription and hyperactivate 
cyclin/CDK complexes by the activation of CDC25 
phosphatases and CDK kinases [54]. It has been proposed 
that the synthetic lethality based on the inhibition of CDK 
may be an interesting method for the treatment of tumors 
with MYC up-regulation [54]. However, we hypothesized 
that this approach is promising only in a subset of GC with 
highest MYC expression.
MYC is able to regulate several processes, including 
apoptosis, proliferation, cell growth, differentiation, 
angiogenesis, and cell metabolism [55]. Here, MYC 
silencing is able to reduce cancer cell proliferation, 
invasion and migraion in vitro in agreement with previous 
studies [56–59]. Although we observed that MYC induces 
cell proliferation, GC cells without MYC silencing 
presented more cells at G1 phase than MYC-silenced cells 
after 72 h of culture. This finding is probably due to the 
rapid accumulation in G1 phase just before confluence 
observed in controls cells, which therefore were not able 
to progress through the cell cycle even with active MYC.
All studied tumors presented increased MYC 
mRNA expression, and most of the tumors presented 
increased protein expression in relation to paired non-
neoplastic specimens. As described by our group in a 
smaller cohort [34], MYC increased expression was 
associated with intestinal-type, deeper tumor extension 
and the presence of metastasis. Elevated expression 
of MYC was also associated with late-onset and 
advanced stage. In a previous study of our group, we 
reported that MYC amplification, which was associated 
with its immunoreactivity, was associated with these 
clinicopathological characteristics [34]. Moreover, MYC 
expression continuously increased during GC progression, 
with the highest expression detect in stage IV tumors. 
Thus, MYC deregulated expression is a common finding 
in GC, especially in intestinal-type and late-onset tumors, 
and has a role in poor prognosis.
In conclusion, decreasing YWHAE and increasing 
CDC25B expression seems to be important for tumor 
development, especially in diffuse-type tumors of 
early-onset. Conversely, increased MYC expression is 
a common finding in GC, especially in intestinal-type 
and late-onset tumors, and has a role in poor prognosis. 
In GC cell lines, YWHAE is able to regulate the GC cell 
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proliferation, invasion and migration through the reduction 
of MYC and CDC25B expression. On the other hand, 
MYC also regulates the GC cell proliferation, invasion 
and migration through the induction of CDC25B and the 
reduction of YWHAE. In the tumor initiation, the opposite 
role of the possible tumor suppressor YWHAE and 
oncogene CDC25B in gastric carcinogenesis seems to be 
independent of MYC expression. However, the inversely 
correlation between YWHAE and MYC expression seems 
to be important for GC cells invasion and migration. The 
inverse correlation between these genes was only detected 
in a subset of GC, including GC samples at stage IV. 
Thus, the interaction between YWHAE and MYC and the 
activation of the pathways related to this interaction may 
be restricted to a subset of GC and may play a role in the 
metastasis process.
MATERIALS AND METHODS
Cell lines and culture
Three GC cell lines previously established and 
characterized by our group were used: AGP01, ACP02, 
and ACP03 [43]. The three cell lines present chromosome 
8 trisomy and MYC amplification [43, 46].
A cell culture of non-neoplastic gastric mucosa cells 
(Normal Gastric Mucosa Cell Line 01, MNP01) pooled 
from 10 patients without gastric cancer was also used 
to initially evaluate the gene and protein expression of 
YWHAE, CDC25B, and MYC.
Cell were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco/Invitrogen, Germany) 
supplemented with 10% fetal bovine serum (Gibco/
Invitrogen, Germany), 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 0.25 μg/ml amphotericin B. All cultures 
were maintained in a 5% CO2 air-humidified atmosphere 
at 37°C.
Gene expression depletion by small interfering 
RNA (siRNA) transfection
An amount of 3×105 cells were seeded into 6 cm2 
plates for each cell line before transfection. Cells were 
cultured for 24 h until cell density was approximately 
50%. For YWHAE and CDC25B silencing, the cells were 
transfected into AGP01, ACP02, and ACP03 cell lines 
using either Silencer Select siRNA specific for YWHAE 
(s16; #4390824; Ambion, USA) and CDC25B (s2753; 
#4390824; Ambion, USA), respectively, or the Silencer 
select negative control #1 (#4390843; Ambion, USA). 
For MYC silencing, a pool of four different double-
stranded siRNAs targeting MYC (20 μM; SMARTpool 
ON-TARGETplus MYC siRNA, L-003282-02-0020; 
GE Healthcare Dharmacon, USA) or scrambled control 
siRNAs (ON-TARGETplus Nontargeting Pool, D-001810-
10-05; GE Healthcare Dharmacon, USA) were transfected 
into AGP01, ACP02, and ACP03 cell lines using 
Lipofectamine RNAiMAX Transfection Reagent (Life 
Technologies, USA).
All siRNA experiments were performed three times.
Cell proliferation by direct counting
After 24, 48, and 72 h of siRNA transfection, 
AGP01, ACP02, and ACP03 cells were harvested 
and directly counted in Neubauer chambers. The total 
number of cells was estimated and used to determine cell 
proliferation. Each sample was repeated three times and 
all experiments were carried in triplicates.
Cell cycle analysis by flow cytometry
For this analysis, siRNA transfection as carried for 72 
h. Cells were treated with 10 μM BrdU for 60 min and then 
trypsinized and fixed in 80% ethanol at -20 °C overnight. 
The cell pellet was then treated with 2 M HCl/0.5% Triton 
X-100 for 30 min at room temperature, neutralized with 0.1 
M Na2B4O7, and stained with FITC-anti BrdU antibodies. 
After centrifugation at 1000 rpm for 5 to 7 min, 400 μL 
propidium iodide (PI)-RNase solution (final concentrations: 
38 mM Na
3
C6H5O7+69 μM PI+1 μL of 10 mg/mL RNase 
A) was added to the pellet and mixed well. Samples were 
incubated at room temperature in the dark for 30 min at 37 
°C before analysis by BD FACSCanto™ II (BD Biosciences, 
USA) flow cytometer. Each sample was repeated three 
times. The forward light scatter (FSC) of nonfixed cells was 
used as a relative measure of cell size.
Invasion and migration analysis
For these analyses, siRNA transfection as carried 
for 24 h. Invasion assay was done in a 24-well transwell 
chamber. Cells were added to coated filters in 100 μL 
of serum-free medium. In the lower compartments of 
the chambers, 600 μL of human fibroblast serum-free-
conditioned media was used as chemo attractant. After 18 
h at 37 °C in a 5% CO2 incubator, the Matrigel coating on 
the upper surface of the filter was wiped off using a cotton 
swab. Cells that migrated through the filters were fixed, 
stained with crystal violet, photographed, and counted.
For the migration analysis, cells were loaded on 
transwell polycarbonate membrane inserts. The plates 
were incubated for 18 h at 37 °C in a 5% CO2 incubator, 
the cells in the lower wells were fixed, stained with crystal 
violet, and counted. The cells that had migrated to the 
lower compartment of the chambers were trypsinized and 
counted.
Each experiment was carried out in triplicate.
Patients and tissue specimens
We enrolled 129 patients with GC who underwent 
surgical resection with curative intent from Northern 
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Brazil. All patients had negative histories of exposure 
to either chemotherapy or radiotherapy before surgery. 
Patients with co-occurrence of other diagnosed cancers 
were excluded from this study. Signed informed consent 
was obtained from all patients before sample collection. 
The study protocol was approved by the Ethics Committee 
of the Hospital Universitário João de Barros Barreto 
(Protocol #316737).
Part of each dissected tumor sample was formalin 
fixed and paraffin embedded (FFPE). Sections of the 
FFPE tissue were stained with hematoxylin and eosin for 
histological evaluation or used for immunohistochemical 
(IHC) analysis. Additional portions of each tumor and 
paired non-neoplastic tissue specimens were snap frozen 
in liquid nitrogen and stored at -80 °C until protein and 
nucleic acid purification.
All samples were classified according to Laurén [60] 
and the tumors were staged according to the tumor-node-
metastasis (TNM) staging criteria [61]. The presence of 
Helicobacter pylori in gastric samples was detected by 
the rapid urease test, and its virulence factor cytotoxicity-
associated gene A (CagA gene) was detect by polymerase 
chain reaction (PCR) using DNA purified simultaneously 
with proteins and mRNA, as previously performed by our 
group [62]. Epstein-Barr virus (EBV) was detected by 
RNA in situ hybridization [62].
DNA/RNA/protein purification
Total RNA and proteins were extracted with TRIzol 
reagent from GC cell lines after 48 h of transfection. 
Total protein, mRNA, and DNA were simultaneously 
isolated from gastric tissue samples using the AllPrep 
DNA/RNA/Protein Kit (Qiagen, Germany) according to 
the manufacturer’s instructions. The protein pellet was 
dissolved in a buffer containing 7 M urea, 2 M thiourea, 
4% CHAPS, 50 mM DTT, 1% Protease Inhibitor Cocktail 
(Sigma-Aldrich, USA), and 0.5% each of Phosphatase 
Inhibitor Cocktail 1 and 2 (Sigma-Aldrich, USA), as 
previously performed by our group [15]. The protein 
concentrations were determined by the method of 
Bradford (Sigma-Aldrich, USA). The RNA concentration 
and quality were determined using a NanoDrop 
spectrophotometer (Kisker, Germany) and 1% agarose 
gels, respectively. Samples were stored at -80 °C until use.
mRNA expression
RNA was reverse transcribed using the Reverse 
Transcription System according to the manufacturer’s 
protocol (A3500; Promega, USA). Complementary DNA 
was then amplified by real-time reverse transcription 
quantitative PCR (RT-qPCR) using TaqMan probes 
purchased as Assays-on-Demand Products for Gene 
Expression (Life Technologies, USA) and a 7500 Fast 
Real-Time PCR instrument (Life Technologies, USA). 
The ACTB gene was selected as an internal control [63]. 
All RT-qPCRs were performed in triplicate for both 
the target genes (YWHAE: Hs00356749_g1; CDC25B: 
Hs00244740_m1; MYC: Hs00153408_m1) and the 
internal control (ACTB: 4333762F).
The relative quantification (RQ) of gene expression 
was calculated according to Livak and Schmittgen [64]. 
In tissue sample analyses, the corresponding control 
sample was designated as a calibrator from each tumor. 
In the cell line analysis, the siRNA control-transfected 
cells were used as a calibrator. The gene expression in 
the MNP01 was also designated as a calibrator from all 
GC cell lines.
Western blotting
Western blot analysis was performed as described 
previously [15]. Reduced protein (25 μg) from each 
sample was separated by 12.5% homogeneous sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and electroblotted onto a polyvinylidene 
fluoride (PVDF) membrane (Hybond-P; GE Healthcare, 
USA). The PVDF membrane was blocked with 
phosphate-buffered saline containing 0.1% Tween 20 and 
5% low fat milk and incubated overnight at 4 °C with 
the corresponding primary antibodies: anti-YWHAE 
(dilution 1:1000; PA5-29773; Life Technologies, 
USA), anti-CDC25B (dilution 1:1000; PA5-14100; 
Life Technologies, USA), anti-MYC (dilution 1:50; 
MA5-12080; Life Technologies, USA), and anti-ACTB 
(dilution 1:250; Ac-15; Life Technologies, USA). After 
extensive washing, a peroxidase-conjugated secondary 
antibody was added for 1 h at room temperature. 
Immunoreactive bands were visualized using the 
Western blotting Luminol reagent, and the images were 
acquired using an ImageQuant 350 digital image system 
(GE Healthcare, Sweden). ACTB was used as a loading 
reference control.
Immunohistochemical staining and scoring
Tumor tissue sections (3 or 4 mm thick) were 
deparaffinized in xylene and rehydrated in a graded series 
of ethanol. After heat-induced epitope retrieval, the tissue 
sections were incubated with primary mouse monoclonal 
antibodies against YWHAE (dilution 1:100; PA5-29773; 
Life Technologies, USA), CDC25B (dilution 1:10; PA5-
14100; Life Technologies, USA) or MYC (dilution 1:100; 
MA5-12080; Life Technologies, USA). A universal 
peroxidase-conjugated secondary antibody kit (LSAB 
System; DakoCytomation, USA) was used for detection. 
We used 3,3’-diaminobenzidine/H2O2 (DakoCytomation, 
Denmark) as the chromogen and hematoxylin as the 
counterstain. A protein immunoreactivity-positive sample 
was defined as one having 10% or more neoplastic cells 
that were positive for the protein.
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Statistical analysis
The data are shown as the frequency, median, and 
IQR. The Shapiro-Wilk test was used to evaluate the 
distribution of the age, mRNA, and protein expression 
data and to determine the appropriate subsequent test 
for statistical comparisons. The Mann-Whitney test was 
used to investigate the possible associations between gene 
mRNA or protein expression and categorical variables, 
such as immunoreactivity and clinicopathological 
features. An association between categorical variables 
was analyzed using the χ2 test. The K-means clustering 
method was used to group samples based on their gene 
expression similarities. A Spearman correlation test was 
used to evaluate the possible correlation between mRNA 
and protein expression. p≤0.05 was considered significant. 
The Bonferroni adjustment of the p value was applied 
when multiple comparisons were performed, with the α 
level being divided by the number of comparisons.
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